Literature DB >> 26159195

Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin.

Ramesh K Paidi, Dominic N Nthenge-Ngumbau, Raghavendra Singh, Thulasi Kankanala, Hina Mehta, Kochupurackal P Mohanakumar1.   

Abstract

BACKGROUND: Bilateral intracerebroventricular (ICV) administration of streptozotocin (STZ) causes Alzheimer's disease (AD)-type neurodegeneration in rats. The model is increasingly used for investigating pathology and therapeutic strategies for AD.
OBJECTIVE: The present study investigated cognitive abilities in rats infused with STZ-ICV in relation to hippocampal and cortical mitochondrial functions during a period of 60 days.
METHODS: Cognitive functions were assayed in rats employing various mazes. Mitochondrial state-3-respiration, complex-I activity and dynamin related protein-1 (DRP-1) expression were measured respectively by oxygraph, spectrophotometry and immunoblot assay. Amyloidosis was investigated employing Congo red staining.
RESULTS: One-time ICV-STZ infused animals exhibited body-weight loss and impaired cognitive ability from 14(th) day post-infusion. A significant loss of mitochondrial electron transport chain complex-I activity in the hippocampi and cortices was found by 14 days, and persisted up to 60 days following ICV-STZ infusion. Mitochondrial state-3 respiration was unaltered in these brain regions by 14 days, but significantly decreased from 21 days after STZ administration. DRP-1 expression was significantly increased in the hippocampi and cortices of these animals 21 days after infusion, but persisted only in the hippocampi up to 60 days. Congophilic granules indicative of amyloidosis were detected in the hippocampus by 21 days.
CONCLUSION: Our results suggest that the non-genetic sporadic AD (sAD) rat model developed by single-time STZ-ICV infusion exhibits protein aggregation and dementia probably resulting from increased mitochondrial fragmentation and functional aberrations. The present study reinforces the validity of this model for studying pathogenesis and potential therapies of sAD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26159195     DOI: 10.2174/1567205012666150710112618

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  11 in total

1.  Vitamin D3 attenuates cognitive deficits and neuroinflammatory responses in ICV-STZ induced sporadic Alzheimer's disease.

Authors:  P Yamini; R S Ray; Kanwaljit Chopra
Journal:  Inflammopharmacology       Date:  2017-07-12       Impact factor: 4.473

2.  Quercetin Exhibits α7nAChR/Nrf2/HO-1-Mediated Neuroprotection Against STZ-Induced Mitochondrial Toxicity and Cognitive Impairments in Experimental Rodents.

Authors:  Niraj Kumar Singh; Debapriya Garabadu
Journal:  Neurotox Res       Date:  2021-09-23       Impact factor: 3.911

3.  The effect of chronic stress and its preconditioning on spatial memory as well as hippocampal LRP1 and RAGE expression in a streptozotocin-induced rat model of Alzheimer's disease.

Authors:  Zohreh Taghadosi; Asadollah Zarifkar; Vahid Razban; Hadi Aligholi
Journal:  Metab Brain Dis       Date:  2022-08-05       Impact factor: 3.655

4.  Brain activities of streptozotocin-induced diabetic Wistar rats treated with gliclazide: Behavioural, biochemical and histomorphology studies.

Authors:  Moses B Ekong; Francis N Odinukaeze; Amaobi C Nwonu; Christopher C Mbadugha; Agnes A Nwakanma
Journal:  IBRO Neurosci Rep       Date:  2022-04-14

5.  Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.

Authors:  Ming Tong; Raiane Leão; Gina V Vimbela; Emine B Yalcin; Jared Kay; Alexander Krotow; Suzanne M de la Monte
Journal:  Mol Cell Neurosci       Date:  2017-04-21       Impact factor: 4.314

Review 6.  Sweet Mitochondria: A Shortcut to Alzheimer's Disease.

Authors:  Paula I Moreira
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 7.  Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future?

Authors:  Simon M Bell; Katy Barnes; Matteo De Marco; Pamela J Shaw; Laura Ferraiuolo; Daniel J Blackburn; Annalena Venneri; Heather Mortiboys
Journal:  Biomedicines       Date:  2021-01-11

Review 8.  Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer's Disease.

Authors:  Chanchal Sharma; Sehwan Kim; Youngpyo Nam; Un Ju Jung; Sang Ryong Kim
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

9.  Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.

Authors:  Ming Tong; Cesar Dominguez; John Didsbury; Suzanne M de la Monte
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-06-03

10.  The Impact of Acetyl-CoA and Aspartate Shortages on the N-Acetylaspartate Level in Different Models of Cholinergic Neurons.

Authors:  Marlena Zyśk; Monika Sakowicz-Burkiewicz; Piotr Pikul; Robert Kowalski; Anna Michno; Tadeusz Pawełczyk
Journal:  Antioxidants (Basel)       Date:  2020-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.